Literature DB >> 10201891

Cutting edge: species specificity of the CC chemokine 6Ckine signaling through the CXC chemokine receptor CXCR3: human 6Ckine is not a ligand for the human or mouse CXCR3 receptors.

C H Jenh1, M A Cox, H Kaminski, M Zhang, H Byrnes, J Fine, D Lundell, C C Chou, S K Narula, P J Zavodny.   

Abstract

The CC chemokine known as 6Ckine (SLC, Exodus-2, or TCA4) has been identified as a ligand for CCR7. Mouse 6Ckine has also been shown to signal through mouse CXCR3 and share some of the activities of IFN-gamma inducible protein 10 and monokine induced by IFN-gamma. Nonetheless, human 6Ckine has not been shown to bind CXCR3 receptor or have angiostatic activity. In this study, we report that human 6Ckine does not induce a calcium flux in either human CXCR3 or mouse CXCR3 transfected cells, although it is an equally potent agonist as mouse 6Ckine and human macrophage inflammatory protein-3beta in human CCR7 transfected cells. Mouse 6Ckine (but not human 6Ckine) is capable of competing with radiolabeled IFN-gamma inducible protein 10 for human CXCR3. In addition, radiolabeled human 6Ckine does not bind to either human CXCR3 or mouse CXCR3. Together these data suggest that human CC chemokine 6Ckine is not a ligand for the human or mouse CXC chemokine receptor CXCR3.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10201891

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.

Authors:  Yang Xu; Ming Zhang; Carlos A Ramos; April Durett; Enli Liu; Olga Dakhova; Hao Liu; Chad J Creighton; Adrian P Gee; Helen E Heslop; Cliona M Rooney; Barbara Savoldo; Gianpietro Dotti
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

2.  Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity.

Authors:  P Romagnani; F Annunziato; L Lasagni; E Lazzeri; C Beltrame; M Francalanci; M Uguccioni; G Galli; L Cosmi; L Maurenzig; M Baggiolini; E Maggi; S Romagnani; M Serio
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

3.  Lymphoid tissue homing chemokines are expressed in chronic inflammation.

Authors:  P Hjelmström; J Fjell; T Nakagawa; R Sacca; C A Cuff; N H Ruddle
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

4.  Human eosinophils express functional CCR7.

Authors:  Praveen Akuthota; Shigeharu Ueki; Jessica Estanislau; Peter F Weller
Journal:  Am J Respir Cell Mol Biol       Date:  2013-06       Impact factor: 6.914

5.  The strict regulation of lymphocyte migration to splenic white pulp does not involve common homing receptors.

Authors:  Martijn A Nolte; Alf Hamann; Georg Kraal; Reina E Mebius
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

6.  Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts to immunodeficient mice.

Authors:  Elizabeth M Pierce; Kristin Carpenter; Claudia Jakubzick; Steven L Kunkel; Kevin R Flaherty; Fernando J Martinez; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

7.  Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity.

Authors:  Chun-min Liang; Cui-ping Zhong; Rui-xia Sun; Bin-bin Liu; Cheng Huang; Jie Qin; Shuang Zhou; Junling Shan; Yin-kun Liu; Sheng-long Ye
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

8.  Intratumoral administration of secondary lymphoid chemokine and unmethylated cytosine-phosphorothioate-guanine oligodeoxynucleotide synergistically inhibits tumor growth in vivo.

Authors:  So Mi Oh; Keunhee Oh; Dong-Sup Lee
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

9.  CCL21/CCR7 promotes G2/M phase progression via the ERK pathway in human non-small cell lung cancer cells.

Authors:  Ying Xu; Lifeng Liu; Xueshan Qiu; Lili Jiang; Bo Huang; Haiying Li; Zixuan Li; Wenting Luo; Enhua Wang
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

10.  A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection.

Authors:  Chung-Her Jenh; Mary Ann Cox; Long Cui; Eva-Pia Reich; Lee Sullivan; Shu-Cheng Chen; David Kinsley; Shiguang Qian; Seong Heon Kim; Stuart Rosenblum; Joseph Kozlowski; Jay S Fine; Paul J Zavodny; Daniel Lundell
Journal:  BMC Immunol       Date:  2012-01-10       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.